Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Insulin 130

Insulin Marketing Sales Compliance 130

Pharmaceutical Technology

MARCH 15, 2023

Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes. Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes.

Insulin 147

Insulin Production Branding Marketing 147

Pharmaceutical Technology

MAY 26, 2023

Chronic disease tech company Convatec Group has partnered with Beta Bionics to manufacture the insulin delivery system iLet Bionic Pancrease. According to Beta Bionics, this is the only first and only automated insulin delivery system that carries 100% of doses and does not require carb counting.

Insulin 147

Insulin Manufacturing Pharmacy Marketing 147

Pharmaceutical Technology

SEPTEMBER 21, 2023

The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.

Insulin 147

Insulin FDA Approval Marketing 147

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130

Insulin Drugs Production Hormones 130

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

BioSpace

MAY 14, 2024

Crackdowns on drug pricing have forced one major insulin out of the market. Are more to come?

Insulin 93

Insulin Marketing Sales Drugs 93

BioPharma Reporter

MAY 5, 2022

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 127

Insulin Clinical Trials Clinical Trials FDA Approval 127

XTalks

OCTOBER 28, 2024

Diabetes, a chronic condition marked by high blood glucose levels due to insulin issues, brings complications like heart disease, stroke, neuropathy and diabetic foot ulcers. Abbot also joined Medtronic to pair its sensors with the latter’s automated insulin delivery (AID) systems. The US DFU treatment market , part of a projected $7.2

Insulin 105

Insulin FDA Approval Marketing Doctor 105

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

Fierce Pharma

MARCH 22, 2024

. | With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once weekly basal insulin icodec) to the market. It was one of several opinions handed down by the CHMP.

Insulin 127

Insulin Sales Medicine Production 127

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Drugs 105

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 In absolute terms, there were 0.73 events for the once-daily drug.

Insulin 98

Insulin Trials Drugs Production 98

STAT News

OCTOBER 6, 2022

The three companies that dominate the global market for insulin have launched various programs to expand the reach of their medicines in dozens of low and middle-income countries — but their efforts remain patchy and equitable access consequently remains out of reach, according to a new analysis.

Insulin 111

Insulin Regulation Manufacturing Medicine 111

pharmaphorum

JULY 29, 2021

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus. Biosimilars marketed in the US typically have list prices 15% to 35% lower than their reference products at launch.

Insulin 98

Insulin Drugs Production Generic Drugs 98

pharmaphorum

NOVEMBER 11, 2022

But none of that stopped the stock market from responding to the bogus announcement with very real movement — Lilly’s stock dropped $42 (11.4%) at its lowest point and has still not recovered. That’s why other insulin stocks are falling too. Sanofi and Novo Nordisk saw similarly dramatic drops.

Insulin 98

Insulin Branding Production Marketing 98

pharmaphorum

FEBRUARY 18, 2025

Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog

Insulin 76

Insulin FDA Approval Marketing 76

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Development 98

Fierce Pharma

NOVEMBER 18, 2022

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim. fkansteiner. Fri, 11/18/2022 - 11:01.

Insulin 82

Insulin Marketing 82

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Marketing 119

Marketing Insulin HR Production 119

Drug Channels

SEPTEMBER 15, 2023

Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products.

Insulin 97

Insulin Manufacturing Drugs Research 97

BioSpace

JUNE 2, 2022

The results showed that insulin icodec is as non-inferior to Sanofi’s insulin glargine, Lantus, potentially bringing another major competitor into the insulin space.

Insulin 75

Insulin Marketing 75

STAT News

MARCH 16, 2023

Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The change comes after Eli Lilly and then Novo Nordisk announced plans this month to reduce list prices for some of their own insulin products by similar amounts. The moves will go into effect on Jan.

Insulin 98

Insulin Manufacturing Production Marketing 98

STAT News

MARCH 3, 2023

… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. plans to sell low-cost insulin. plans to sell low-cost insulin. And the Mark Cuban Cost Plus Drug Co.

Insulin 98

Insulin Drugs Production Marketing 98

BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 95

Insulin Drug Delivery Development Drugs 95

Fierce Pharma

JULY 11, 2024

In surging to the top spot in the market cap rankings in Europe, Novo Nordisk has been on an extended winning streak. | The FDA has slowed the roll for Novo Nordisk, rejecting its once-a-week insulin icodec for patients with Type 1 and Type 2 diabetes. In a complete response letter, the U.S.

Insulin 82

Insulin Manufacturing Regulation Marketing 82

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes. The drug candidate is administered as an subcutaneous formulation.The combination acts by targeting GLP-1R and insulin receptor.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

STAT News

MARCH 17, 2023

Enjoy, and see you soon … Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The three companies are the largest manufacturers of insulin and collectively hold a dominant 80% share of the market. Continue to STAT+ to read the full story…

Insulin 98

Insulin Research Drugs Manufacturing 98

XTalks

MARCH 26, 2021

In Episode 1 of the Xtalks Life Science Podcast, Sarah discusses a new condition called “Mask-Associated Dry Eye” and Ayesha talks about Droplet Micron, an innovative insulin needle. Patient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet Micron.

Life Science 76

Life Science Insulin Sales Marketing 76

pharmaphorum

NOVEMBER 26, 2021

Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues next year. The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk.

Insulin 59

Insulin Production Sales Marketing 59

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. The initial therapeutic focus is diabetes, with three insulin-based products in development.

Insulin 52

Insulin Production Marketing Pharma Companies 52

Pharmaceutical Technology

DECEMBER 12, 2022

Pipeline therapies within the cardiometabolic space have recently gathered interest following the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference, which took place on 1–3 December.

Compliance 264

Compliance Insulin Marketing Trials 264

Drug Channels

APRIL 26, 2022

In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr. Glaucomflecken helps UnitedHealthcare celebrate Doctors’ Day!

Pharmacy 98

Pharmacy Insulin Doctors Doctor 98

Pharmaceutical Technology

APRIL 28, 2023

Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn. The significant sales growth of Ozempic reinforces its continued dominance in the type 2 diabetes market.

Sales 130

Sales Insulin Marketing FDA Approval 130

Camargo

OCTOBER 14, 2020

The FDA has announced its approval of a bluetooth-controlled insulin delivery and monitoring system for use in pediatric patients ages 2 through 6 with Type 1 diabetes. Although the device automatically adjusts insulin levels, patients or their caregivers need to request insulin doses manually to counter carbohydrate consumption at mealtime.

Development 196

Development Insulin Drug Delivery Production 196

XTalks

SEPTEMBER 9, 2024

Boston Scientific is transforming heart health with its less invasive treatments, and Medtronic continues to push the boundaries with advanced insulin delivery systems and real-time glucose monitoring. Abbott Laboratories (ABT) Market Capitalization : $267.1 Intuitive Surgical (ISRG) Market Capitalization : $224.5

Marketing 105

Marketing Insulin Sales Big Data 105

World of DTC Marketing

DECEMBER 3, 2021

Until you hear from someone who has drained their savings to fight cancer or can’t afford insulin, you’re working in a state of denial. We should talk about patients as people; they are not market segments. Empathy is a powerful tool in DTC marketing and should be required for every DTC manager.

Insulin 259

Insulin Vaccine Vaccination Marketing 259